Acquisition Opportunity Medicinal Genomics was acquired in 2025 by Courtagen Life Science, signaling a potential consolidation pathway or cross-sell opportunity with Courtagen’s epilepsy, mitochondrial disease, and autism focus. Explore integration of microbial testing solutions into Courtagen’s portfolio and existing customer base.

Cannabis Expertise Pioneering cannabis genome sequencing and strain validation positions MGC as a trusted partner for cannabis producers seeking safety, authenticity, and quality assurance. Target cannabis cultivators, processors, and compliance teams with genomics-based identity verification and seed-to-sale traceability solutions.

Automation Demand Interest in automated qPCR microbial testing for cannabis, supplements, natural products, and food suggests strong demand for scalable, hands-off testing workflows. Offer integrated automation kits, validated assays, and turnkey lab automation consulting to labs expanding capacity.

Bioinformatics Value In-house DNA sequencing and bioinformatics capabilities create opportunities to upsell data analysis services, genetic interpretation, and reporting. Propose premium data analytics, custom dashboards, and regulatory-grade certification packages for microbial safety claims.

Partnership Network Past collaborations with Bio Molecular Systems and UgenTec indicate openness to ecosystem partnerships. Leverage partner-friendly collaboration models to co-sell, co-develop, or integrate with software and hardware vendors serving agriculture, biotech, and life sciences testing labs.